65 GROVE STREET, WATERTOWN, MA
Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
Reports Second Quarter 2026 Financial Results and Provides Business Update
2026 Annual Meeting Results - Election of Three Class I Directors
Announces Strategic Licensing Agreement to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
Investor Presentation
Reports First Quarter 2026 Financial Results and Provides Business Update
Financial Results, Press Release
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Post-Effective Amendment to Registration Statement
Prospectus filed pursuant to Rule 424(b)(7)
Correspondence